SARCLISA SIMPRE Trademark

Trademark Overview

On Tuesday, December 12, 2023, a trademark application was filed for SARCLISA SIMPRE with the United States Patent and Trademark Office. The USPTO has given the SARCLISA SIMPRE trademark a serial number of 98310452. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, January 14, 2025. This trademark is owned by Sanofi. The SARCLISA SIMPRE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of multiple myeloma
sarclisa simpre

General Information

Serial Number98310452
Word MarkSARCLISA SIMPRE
Filing DateTuesday, December 12, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, January 14, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of multiple myeloma
Translation of Words in MarkThe English translation of "SIMPRE" in the mark is "yes".

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSanofi
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParis 75017
FR

Trademark Events

Event DateEvent Description
Tuesday, December 12, 2023NEW APPLICATION ENTERED
Wednesday, December 27, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, March 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 26, 2024ASSIGNED TO LIE
Thursday, July 11, 2024ASSIGNED TO EXAMINER
Thursday, July 18, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 18, 2024NON-FINAL ACTION WRITTEN
Thursday, July 18, 2024NON-FINAL ACTION E-MAILED
Monday, August 26, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 8, 2024NON-FINAL ACTION E-MAILED
Wednesday, June 26, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Monday, August 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 8, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 30, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, November 16, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 8, 2024NON-FINAL ACTION WRITTEN
Saturday, November 16, 2024NON-FINAL ACTION E-MAILED
Tuesday, January 14, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 14, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 14, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, November 16, 2024NON-FINAL ACTION WRITTEN

Related Keywords

simpre sarclisa preparations pharmaceutical treatment myeloma multiple cancer oncology